Changes in Essential Cancer Medicines and Their Impact on Cancer Outcomes
Author Information
Author(s): Ul Haq Moizza Zia, Heredia Camila, Buadu Adelaide, Rizvi Amal, Workentin Aine
Primary Institution: MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health Toronto
Hypothesis
This study examines the association between amenable cancer mortality and the listing of medicines used in the management of eight cancers in national essential medicines lists of 158 countries.
Conclusion
There was an association between listing cancer medicines on national essential medicines lists and cancer mortality.
Supporting Evidence
- Associations were found between cancer medicine listing and outcomes for six of the eight examined cancers.
- The most commonly listed medicines included methotrexate, medroxyprogesterone, tamoxifen, and cyclophosphamide.
- New cancer medicines were added to the essential medicines lists since 2017.
- Healthcare expenditure and population size were adjusted for in the analysis.
Takeaway
The study found that countries with more cancer medicines listed in their essential medicines lists tend to have lower cancer death rates.
Methodology
A cross-sectional examination of national essential medicines lists for 158 countries was conducted, and multiple linear regressions were used to analyze the association between the number of medicines listed and cancer mortality.
Potential Biases
There may be biases related to the availability and accessibility of listed medicines in different countries.
Limitations
The study may not account for other factors affecting cancer outcomes, such as access to healthcare and the availability of treatments.
Participant Demographics
The study included data from 158 countries, but specific demographic details of participants were not provided.
Statistical Information
P-Value
p=0.001 for non-melanoma skin cancer, p=0.006 for uterine cancer, p=0.001 for breast cancer, p=0.021 for Hodgkin lymphoma, p=0.006 for colon cancer, p=0.002 for leukemia.
Confidence Interval
Lower 95% CI and Upper 95% CI were reported for various cancers but not specified in the summary.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website